AKT1 and neoplasm: These in silico findings suggest that both drugs may potentially influence tumor-related processes by interacting with multiple molecular targets, including signaling kinases (e.g., PI3K, AKT1, mTOR, B-RAF), transcription factors (MITF, HIF1A, NF-κB), and proteins involved in tumor microenvironment remodeling (MMPs, VEGF-A, CD117).